Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 01, 2025

Q1 2025 Earnings Preview: Friday, May 2, 2025

Economic Backdrop

The global economic outlook for 2025 is characterized by cautious optimism. The IMF projects global growth at 3.3% for 2025, with advanced economies growing at 1.8% and emerging markets at 4.2%. However, risks are tilted to the downside, primarily due to escalating trade tensions and policy uncertainty. Recent tariff announcements and geopolitical challenges have introduced volatility into financial markets. Global headline inflation is expected to decline to 4.2% in 2025, but services inflation continues to complicate monetary policy, with central banks likely maintaining higher interest rates. Consumer sentiment remains subdued, particularly in advanced economies, where concerns over rising costs and economic stability are prevalent. Against this backdrop, these earnings reports will reveal how companies are navigating these challenges.

Sector-by-Sector Analysis

Energy Sector

The energy sector, represented by Exxon Mobil (XOM), Chevron (CVX), Shell (SHEL), and Imperial Oil (IMO), faces significant challenges due to lower oil prices. As of May 1, 2025, crude oil prices have dropped to approximately $56.78 per barrel, a 19.53% decline since the beginning of the year, driven by trade tensions and OPEC+ production increases.

  • Exxon Mobil (XOM): Exxon Mobil’s Q4 2024 earnings were $7.6 billion, supported by record production in the Permian and Guyana. Q1 2025 earnings are expected to reflect lower oil prices, with analysts forecasting an EPS of $1.86. Investors will focus on cost efficiencies and progress in low-carbon initiatives.
  • Chevron (CVX): Chevron reported Q4 2024 adjusted earnings of $3.6 billion, impacted by weaker refining margins. Analysts expect an EPS of $2.24 for Q1 2025, with attention on upstream production and renewable energy investments.
  • Shell (SHEL): Shell’s Q4 2024 adjusted earnings were $3.7 billion, affected by lower prices and LNG hedging impacts. Q1 2025 EPS is forecasted at $1.66, with investors watching strategic divestments like SPDC in Nigeria and refinery utilization improvements.
  • Imperial Oil (IMO): Imperial Oil’s Q4 2024 earnings beat estimates with an EPS of $1.69, driven by record production. Analysts expect an EPS of $2.16 for Q1 2025, with focus on the Strathcona Renewable Diesel Project and cost reductions.

Why It Matters: The energy sector is highly cyclical, and lower oil prices could pressure margins. However, companies demonstrating operational efficiency and strategic investments in renewables may mitigate these challenges, providing insights into global energy demand and supply dynamics.

Financial Services Sector

The financial services sector, including Apollo Global Management (APO), Cboe Global Markets (CBOE), and NatWest Group (NWG), operates in a complex environment shaped by interest rates, market volatility, and regulatory changes.

  • Apollo Global Management (APO): Apollo’s Q4 2024 results showed record AUM of $733 billion. Analysts expect an EPS of $1.94 for Q1 2025, with investors focusing on asset management growth and retirement services performance.
  • Cboe Global Markets (CBOE): Cboe reported record Q4 2024 net revenue of $532.0 million, driven by robust options volumes. Q1 2025 EPS is forecasted at $2.29, with attention on trading activity and new product launches.
  • NatWest Group (NWG): NatWest’s Q4 2024 results reflected strong performance in retail banking. Analysts expect an EPS of 13.1p for Q1 2025, with focus on net interest margins and digital transformation efforts.

Why It Matters: Financial services earnings reflect broader market confidence and economic stability. Strong results could indicate resilience in capital markets, while weaker performance may signal caution amid higher interest rates and economic uncertainty.

Basic Materials Sector

DuPont de Nemours (DD) represents the basic materials sector, which is sensitive to commodity prices and global demand.

 

  • Wendy’s (WEN): Wendy’s Q4 2024 sales grew 6.2%, with systemwide sales up 5.4%. Analysts expect an EPS of $0.25 for Q1 2025, with focus on same-store sales growth and international expansion plans.

Why It Matters: Consumer discretionary spending reflects consumer confidence and economic health. Strong performance could indicate resilience in dining out, while weaker results may highlight inflation’s impact on discretionary budgets.

Healthcare Sector

Cigna Group (CI) leads the healthcare sector, known for its resilience during economic downturns.

 

  • Cigna Group (CI): Cigna’s Q4 2024 adjusted income was $7.7 billion, with strong growth in Evernorth Health Services. Analysts expect an EPS of $6.52 for Q1 2025, with attention on medical cost trends and the Medicare business divestiture to HCSC.

Why It Matters: Healthcare’s defensive nature makes it a safe haven during economic uncertainty. Investors will look for growth in insurance and pharmacy benefits, as well as strategic shifts in Cigna’s portfolio.

Investor Implications

These earnings reports will likely drive stock price movements and shape market sentiment. Strong performances and optimistic guidance could bolster confidence, while disappointing results may exacerbate volatility. Investors should:

  • Review Primary Sources: Access earnings releases and conference calls on company websites.
  • Analyze Guidance: Forward-looking statements will be critical for assessing future growth, especially given trade and inflation risks.
  • Diversify Investments: Spreading risk across sectors can mitigate volatility, as energy and consumer discretionary firms may face greater challenges, while healthcare remains more stable.

Tickeron: Pioneering AI-Driven Market Analysis

Tickeron is at the forefront of integrating artificial intelligence within the trading landscape. Founded by Ph.D. mathematicians and quantitative researchers, the company has developed an interactive marketplace that consolidates high-quality AI-driven tools for robust market analysis. By automating extensive research processes, Tickeron transforms vast amounts of data into actionable insights that enhance the understanding of market patterns and trends.

Key Innovations:

  • AI-Powered Algorithms: Advanced models that merge technical analysis with machine learning to generate precise trade signals.
  • Comprehensive Trading Tools: Products such as pattern recognition systems, trend prediction engines, and intelligent trading bots that streamline market analysis.
  • Integrated Analytics Platform: A unified ecosystem that aggregates multiple investment resources to support data-rich decision-making across diverse market strategies.

Through these innovations, Tickeron plays a significant role in reshaping how traders approach market research and decision-making in an increasingly complex financial environment.

 Disclaimers and Limitations


Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.